Neogenomics Q3 2026 earnings

NEO · 2026-10-28 16:06 AMC ET · 8-K on SEC

Revenue and adjusted EBITDA grew double-digits, and the company raised full-year revenue guidance.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$209.3M+11.4%—Income Statement (Three Months Ended September 30, – 2026)

Revenue breakdown

SegmentActualYoYShare of revenueNote
Clinical services13% growth+13%100% (Total)Clinical volume +2%, average revenue per test +11% to $530
NGS29% growth+29%Included in Clinical servicesNGS test volume grew 17%

Margins and costs

  • Gross margin 46.2% (prior 42.8%, change +3.4 pp)
  • Operating expenses $105.0M (decrease of $3M, or 3%)
  • One-offs in the quarter Impairment charges (Q3 2025: $7.1M); Gain on extinguishment of debt (Q3 2025: $11.2M); IP litigation costs (Q3 2025: $3.6M)
  • Effective tax rate Not stated
  • Non-GAAP bridge Adds back interest income/expense, tax benefit/expense, depreciation, amortization, leadership transition costs, acquisition and integration expenses, stock-based compensation, gain on extinguishment of debt, impairment charges, IP litigation costs, and contingency for regulatory matter

KPIs

MetricActualPrior quarterPrior yearChange
Cash and cash equivalents$139.3M$159.6M—-$20.3M
Accounts receivable, net$213.4M$159.2M—+$54.2M
Weighted average common shares outstanding (diluted)128,587128,415—+172

Guidance

MetricGuidePrior guideChange
Consolidated revenue$807M - $809M$802M - $806M+$5M - $3M
Adjusted EBITDAApproximately $60M$56M - $58M+$2M - $4M
Adjusted diluted EPS$0.21 - $0.22——

What drove it

  • Revenue story Total revenue increased 11% YoY to $209.3M; Clinical services revenue grew 13% with NGS revenue growing 29% and test volume growing 17%.
  • EPS story Net loss improved to $7.5M from $27.1M YoY, driven by revenue growth, margin expansion, and lower operating expenses.
  • One-off check Impairment charges $0 (Q3 2026) vs $7.1M (Q3 2025); Gain on extinguishment of debt $0 (Q3 2026) vs $11.2M (Q3 2025); IP litigation costs $0.04M (Q3 2026) vs $3.6M (Q3 2025).

The good

  • Adjusted EBITDA increased 53% YoY to $19M
  • Adjusted Gross Profit Margin increased 310 bps YoY to 49%
  • Operating expenses decreased 3% YoY to $105M

The bad

  • Net loss of $7.5M remains negative
  • Cash and cash equivalents decreased $20.3M YoY

The ugly

  • none

Open questions

  • The filing does not disclose the specific revenue mix by segment (e.g., Clinical vs. Research) or the exact dollar amount of NGS revenue.
  • The filing does not disclose the specific impact of the leadership transition costs on the adjusted EBITDA or net income.
Full release

Earnings: NEO — filed 2026-10-28

Neogenomics Inc (NEO) · Form 8-K, Item 2.02 · Filed · SEC filing

NeoGenomics Reports Third Quarter 2026 Results

Total revenue increased 11% YoY to $209 million

Clinical services revenue grew 13%, with NGS revenue growth of 29%

Company raises full-year 2026 revenue and adjusted EBITDA guidance

Fort Myers, Florida (October 28, 2026) - NeoGenomics, Inc. (NASDAQ: NEO) (the

“

Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its third-quarter results for the period ended September 30, 2026.

“Our third-quarter results reinforce that we have the right strategy in place and the right team to execute against it,” said Tony Zook, Chief Executive Officer of NeoGenomics. “Clinical revenue growth of 13% continues to showcase the strength of our broad-based testing solutions portfolio, with NGS revenue growing a strong 29% and NGS test volume growing 17%. As our business continues its shift to higher-value, high-margin testing modalities, we see further opportunity to invest into our commercial teams, community channel strength, and product pipeline. At the same time, we expect to reduce complexity across our business through operational excellence initiatives designed to deliver accelerating growth and disciplined margin expansion over the long-term.”

Third-Quarter Results

Consolidated revenue for the third quarter of 2026 was $209 million, an increase of 11% over the same period in 2025. Clinical volume increased by 2%, while average revenue per clinical test increased by 11% to $530.

Consolidated gross profit for the third quarter of 2026 was $97 million, an increase of 20% compared to the third quarter of 2025. Consolidated gross profit margin, including amortization of acquired intangible assets and stock-based compensation expense, was 46%. Adjusted Gross Profit Margin

(1), excluding amortization of acquired intangible assets and stock-based compensation expense, was 49%, an increase of 310 bps versus the same period in 2025.

NeoGenomics, Inc. | 9490 NeoGenomics Way, Fort Myers, FL 33912

Page

2

Operating expenses for the third quarter of 2026 were $105 million, a decrease of $3 million, or 3%, compared to the third quarter of 2025.

Net loss for the quarter was $8 million compared to net loss of $27 million for the third quarter of 2025.

Adjusted EBITDA

Financial statements

Income Statement

Previous FY 2026 Guidance — The Company is revising its full-year 2026 guidance, as shown below (in millions).

FY 2025 – ActualPrevious FY 2026 Guidance – LowPrevious FY 2026 Guidance – HighUpdated FY 2026 Guidance – LowUpdated FY 2026 Guidance – HighYOY % Change from FY 2025 – LowYOY % Change from FY 2025 – High
Consolidated revenue72780280680780911.0%11.0%
Net loss-108-42-34-32-3070.0%72.0%
Adjusted EBITDA435658Approximately $60Approximately 38%

Income Statement

Three Months Ended September 30, — (unaudited)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
NET REVENUE209,254187,797597,582537,162
COST OF REVENUE112,666107,351328,252306,212
GROSS PROFIT96,58880,446269,330230,950
Operating expenses:General and administrative67,07369,874196,427209,828
Operating expenses:Research and development9,8558,69430,15027,898
Operating expenses:Sales and marketing27,60121,80678,70668,564
Operating expenses:Impairment charges7,08627,127
Operating expenses:Total operating expenses104,529107,460305,283333,417
Operating expenses:LOSS FROM OPERATIONS-7,941-27,014-35,953-102,467
Operating expenses:Interest income1,1961,5633,6837,547
Operating expenses:Interest expense-1,267-603-2,646-3,154
Operating expenses:Other (expense) income, net-9-335-38212
Operating expenses:Gain on extinguishment of debt11,181
Operating expenses:Loss before taxes-8,021-26,389-23,773-97,862
Operating expenses:Income tax benefit (expense)475-7401,359-282
Operating expenses:NET LOSS-7,546-27,129-22,414-98,144
NET LOSS PER SHAREBasic-0.06-0.21-0.17-0.77
NET LOSS PER SHAREDiluted-0.06-0.21-0.17-0.77
WEIGHTED AVERAGE COMMON SHARES OUTSTANDINGBasic128,587128,415129,125127,917
WEIGHTED AVERAGE COMMON SHARES OUTSTANDINGDiluted128,587128,415129,125127,917

Income Statement

Three Months Ended September 30, — (unaudited)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net loss (GAAP)-7,546-27,129-22,414-98,144
Adjustments to net loss:Interest income-1,196-1,563-3,683-7,547
Adjustments to net loss:Interest expense1,2676032,6463,154
Adjustments to net loss:Income tax (benefit) expense-475740-1,359282
Adjustments to net loss:Depreciation8,5558,80325,91227,309
Adjustments to net loss:Amortization8,0237,63423,63024,120
Adjustments to net loss:EBITDA (non-GAAP)8,628-10,91224,732-50,826
Further adjustments to EBITDA:Leadership transition costs(1)1,0733191,6363,149
Further adjustments to EBITDA:Acquisition and integration related expenses(2)1,8008066,176
Further adjustments to EBITDA:Stock-based compensation expense8,83710,30526,68933,274
Further adjustments to EBITDA:Gain on extinguishment of debt-11,181
Further adjustments to EBITDA:Impairment charges(3)7,08627,127
Further adjustments to EBITDA:IP litigation costs(4)423,63420711,077
Further adjustments to EBITDA:Adjustment to contingency for regulatory matter-1,155
Further adjustments to EBITDA:Other significant expenses, net(5)89406
Further adjustments to EBITDA:Adjusted EBITDA (non-GAAP)18,66912,23242,14029,977

Income Statement

Three Months Ended September 30, — (unaudited)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Three Months Ended September 30, – 2025Three Months Ended September 30, – % ChangeNine Months Ended September 30, – 2026Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025Nine Months Ended September 30, – 2025Nine Months Ended September 30, – % Change
Consolidated:Total revenue (GAAP)209,254187,79711.4%597,582537,16211.2%
Consolidated:Cost of revenue (GAAP)112,666107,3515.0%328,252306,2127.2%
Consolidated:Adjustments to cost of revenue(1)-5,029-4,950-15,001-15,389
Consolidated:Adjusted cost of revenue (non-GAAP)107,637102,4015.1%313,251290,8237.7%
Consolidated:Gross profit (GAAP)96,58880,44620.1%269,330230,95016.6%
Consolidated:Adjusted gross profit (non-GAAP )101,61785,39619.0%284,331246,33915.4%
Consolidated:Gross profit margin (GAAP)46.2%42.8%45.1%43%
Consolidated:Adjusted gross profit margin (non-GAAP)48.6%45.5%47.6%45.9%

Income Statement

Three Months Ended September 30, — (unaudited)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net loss (GAAP)-7,546-27,129-22,414-98,144
Adjustments to net loss net of tax:Amortization8,0237,63423,63024,120
Adjustments to net loss net of tax:Leadership transition costs(1)1,0733191,6363,149
Adjustments to net loss net of tax:Acquisition and integration related expenses(2)1,8008066,176
Adjustments to net loss net of tax:Stock-based compensation expense8,83710,30526,68933,274
Adjustments to net loss net of tax:Gain on extinguishment of debt-11,181

Income Statement

Year Ended December 31, 2026

Year Ended December 31, 2026 – Low RangeYear Ended December 31, 2026 – High Range
Net loss (GAAP)-32,000-30,000
Amortization32,00032,000
Stock-based compensation expenses36,00035,000
Other one-time expenses-9,000-9,000
Adjusted net income (non-GAAP)27,00028,000
Interest and taxes-1,000-2,000
Depreciation34,00034,000
Adjusted EBITDA (non-GAAP)60,00060,000
Net loss per diluted share (GAAP)-0.25-0.23
Adjustments to net loss per diluted share:Amortization0.250.25
Adjustments to net loss per diluted share:Stock-based compensation expenses0.280.27
Adjustments to net loss per diluted share:Other one-time expenses-0.07-0.07
Adjustments to net loss per diluted share:Adjusted diluted EPS (non-GAAP)0.210.22
Weighted average assumed shares outstanding in 2026:Diluted shares (GAAP)129,500129,500
Weighted average assumed shares outstanding in 2026:Adjusted diluted shares outstanding (non-GAAP)129,500129,500

Balance Sheet

December 31, 2025 — (in thousands)

September 30, 2026 (unaudited)December 31, 2025
Current assetsCash and cash equivalents139,281159,618
Current assetsAccounts receivable, net213,410159,242
Current assetsInventories25,50028,566
Current assetsPrepaid assets22,77421,443
Current assetsOther current assets9,1187,417
Current assetsTotal current assets410,083376,286
Current assetsProperty and equipment, net85,94484,834
Current assetsOperating lease right-of-use assets77,97878,444
Current assetsFinancing lease right-of-use assets6,29154
Current assetsIntangible assets, net263,628286,528
Current assetsGoodwill523,995524,344
Current assetsOther assets8,9989,340
Current assetsTotal non-current assets966,834983,544
Current assetsTotal assets1,376,9171,359,830
Current liabilitiesAccounts payable and other current liabilities110,17483,496
Current liabilitiesCurrent portion of operating lease liabilities4,2954,776
Current liabilitiesCurrent portion of finance lease liabilities1,70428
Current liabilitiesTotal current liabilities116,17388,300
Long-term liabilitiesOperating lease liabilities64,30362,822
Long-term liabilitiesFinance lease liabilities4,15127
Long-term liabilitiesConvertible senior notes, net374,688341,858
Long-term liabilitiesDeferred income tax liabilities, net16,09718,219
Long-term liabilitiesOther long-term liabilities86712,042
Long-term liabilitiesTotal long-term liabilities460,106434,968
Long-term liabilitiesTotal liabilities576,279523,268
Stockholders’ equityTotal stockholders' equity800,638836,562
Stockholders’ equityTotal liabilities and stockholders’ equity1,376,9171,359,830

Cash Flow

Nine Months Ended September 30, — (unaudited)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
CASH FLOWS FROM OPERATING ACTIVITIESNet loss-22,414-98,144
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Depreciation25,91227,309
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Amortization of intangibles22,90024,120
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Stock-based compensation26,68933,274
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Non-cash operating lease expense4,7645,039
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Non-cash finance lease amortization684

(1) for the third quarter of 2026 increased by 53% to $19 million, compared to $12 million in the third quarter of 2025. Adjusted Net Income

(1) was $11 million compared to Adjusted Net Income

(1) of $4 million in the third quarter of 2025.

Cash and cash equivalents totaled $139 million at quarter end.

(1)

The Company has provided adjusted financial information that has not been prepared in accordance with GAAP, including Adjusted EBITDA, Adjusted Gross Profit Margin, Adjusted Net (Loss) Income, and Adjusted Diluted EPS. Each of these measures is defined in the section of this press release entitled “Use of Non-GAAP Financial Measures.” See also the tables reconciling such measures to their closest GAAP equivalent.

2026 Financial Guidance

The Company is revising its full-year 2026 guidance, as shown below (in millions).

Conference Call

The Company has scheduled a webcast and conference call to discuss its third quarter 2026 results on Wednesday,

October 28, 2026 at 4:30 p.m. Eastern Time. To access the live call via telephone, interested investors should dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code provided for this call is 489662. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, providing oncologists, pathologists, hospital systems, academic medical centers, and pharmaceutical firms with innovative diagnostic and predictive testing to deliver timely, actionable insights that guide personalized care decisions. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, England.

We routinely post information that may be important to investors on our website at https://www.neogenomics.com. Information on, or accessible through, our website is not incorporated by reference into, and is not a part of, this release or any other report or document that we may file with the Securities and Exchange Commission (“SEC”).

Forward Looking Statements

This press release, and the conference call and webcast referenced above, contain forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “target,” “enable,” “intend,” “potential” and other words of similar meaning, although not all forward-looking statements include these words.

These forward-looking statements include, among others, statements regarding the Company’s full-year 2026 financial guidance and the assumptions underlying that guidance; the strategic execution of the Company’s leadership team and the Company’s plans with respect to executive leadership succession, including the anticipated timing and effects thereof; the

NeoGenomics, Inc. | 9490 NeoGenomics Way, Fort Myers, FL 33912

Page

2... (truncated)l position; the Company’s future operating and financial performance; the Company’s growth potential and expected growth drivers, including with respect to next-generation sequencing (NGS) and molecular residual disease (MRD) testing; projected costs and capital expenditures; the Company’s prospects and plans; the Company’s belief in the durability of its broad-based testing solutions portfolio; the Company’s expectations regarding its ability for realizing efficiencies from operational excellence initiatives; estimates of market size and position; and the objectives of management.

Each forward-looking statement contained in this press release, or made during the related conference call and webcast, is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company’s ability to identify and implement appropriate financial and operational initiatives to execute on its strategic priorities; to achieve the revenue, net loss and Adjusted EBITDA results contemplated by its guidance; to realize anticipated efficiencies, cost savings and margin improvement from its operational initiatives, including in light of compensation, benefits and supplies cost inflation; to enter new markets and increase market share in both current and new markets; to continue gaining new customers; to develop, validate and commercialize new types of tests; to obtain and maintain coverage and reimbursement for its tests; to bill and collect for its services on a timely basis and to accurately estimate amounts expected to be collected, including implicit price concessions; to assemble and maintain an effective executive team and retain key personnel, including in connection with its announced leadership succession; to integrate acquired businesses and realize their anticipated benefits; to manage the effects of seasonality and changes in payer mix; and to otherwise implement its business plans. Applicable risks and uncertainties also include the potential impact of evolving regulatory requirements related to laboratory developed tests; the impact of tariffs and trade policy uncertainty on the Company’s supply chain and costs; potential reimbursement or coverage changes by government and commercial payers; the Company’s compliance with, and the cost of complying with, healthcare laws and regulations; risks relating to potential dilution to the Company’s stockholders upon conversion of its outstanding convertible senior notes; the outcome of pending legal proceedings; and the risks identified under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 17, 2026, and in the Company’s other filings with the SEC.

The Company’s full-year 2026 guidance is based on management’s current expectations and assumptions as of the date of this press release. Actual results may differ materially.

The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release or made during the related conference call and webcast. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and forward-looking statements made during the related conference call and webcast speak only as of the date of that call (unless another date is indicated), and the Company undertakes no obligation to update or revise any of these statements, whether as a result of new information, future events or otherwise, except as required by law. Any replay or archived version of the conference call or webcast is provided for convenience only, and the statements made therein are not updated or reaffirmed as of any later date.

Investor Contact

InvestorRelations@neogenomics.com

Media Contact

Andrea Sampson asampson@sampsonprgroup.com

NeoGenomics, Inc. | 9490 NeoGenomics Way, Fort Myers, FL 33912

Page

3

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.